Results 271 to 280 of about 1,610,988 (356)

GLP‐1 agonist‐associated presentations to unscheduled care: An opportunistic pilot study

British Journal of Clinical Pharmacology, EarlyView.
The impact of GLP‐1 or GIP/GLP‐1 receptor agonist use on unscheduled care is not well‐described. We conducted a prospective, observational study using opportunistic screening by clinicians as a first step to understanding the effect of GLP‐1 or GIP/GLP‐1 agonists on Emergency Department presentations and to guide future studies.
Oliver Thomas, James Michael Coulson
wiley   +1 more source

Type 2 Diabetes Mellitus and Macrovascular Complications

International Journal of Endocrinology, 2017
Peng-Fei Shan, Qian Li, Mogher Khamaisi, Gui-fen Qiang   +3 more
doaj   +1 more source

Normal triglyceride concentration and the risk of diabetes mellitus type 2 in the general population of China. [PDF]

Front Endocrinol (Lausanne)
Guo R, Wei L, Cao Y, Zhao W.
europepmc   +1 more source

A systematic review of medication adherence and mortality in chronic disease: Implications for clinical guidelines and policy

British Journal of Clinical Pharmacology, EarlyView.
Objectives This systematic review aims to investigate whether good medication adherence in adults with chronic conditions is associated with a lower mortality risk compared to poor adherence within published literature, and the extent to which this relationship is represented within South African policy and legislation.
Jessica Hamuy Blanco, Dina C. Janse van Rensburg, Audrey Jansen van Rensburg, Corrie Uys, Natalie Schellack   +4 more
wiley   +1 more source

Connections between Cognitive Impairment and Atrial Fibrillation in Patients with Diabetes Mellitus Type 2. [PDF]

Biomedicines
Militaru M, Lighezan DF, Tudoran C, Militaru AG.   +3 more
europepmc   +1 more source

Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia

, 2013
Thomas Paraidathathu, Azuana, Farida Islahudin, Ahmad   +3 more
openalex   +2 more sources

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Global, regional, and national burden of chronic kidney disease due to diabetes mellitus type 2 from 1990 to 2021, with projections to 2036: a systematic analysis for the Global Burden of Disease Study 2021. [PDF]

Front Med (Lausanne)
Hu R, Zhao Z, Xie L, Ma Z, Wu W, Li S.
europepmc   +1 more source

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros   +5 more
wiley   +1 more source